drugset / Trial / NCT06391645
Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis
Phase 2/3
Not yet recruiting
60 enrolled
Beijing Tiantan Hospital
Beijing Healthunion Cardio-Cerebrovascular Disease Prevention and Treatment Foundation · collabBeijing University of Chemical Technology · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Amyotrophic lateral sclerosis (ALS) is one of the most lethal neurodegenerative diseases, with most patients dying from respiratory failure 3-5 years after the onset. The purpose of this study is to explore the efficacy and safety of nerve growth factor (NGF) encapsulated with 2-methacryloyloxyethyl phosphorylcholine (MPC) nanocapsules in the treatment of ALS patients.
Timeline
- Start
- 2024-05
- Primary completion
- 2025-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | nerve growth factor | Cell therapy | 11.84 mg | Intravenous |
| Subject | nerve growth factor | Cell therapy | 19.2 mg | Intravenous |